Polatuzumab vedotin + rituximab + gemcitabine + oxaliplatin (Pola‑R‑GemOx) regimen dosing and supportive care
Pola‑R‑GemOx is administered in 21-day cycles. (onlinelibrary.wiley.com)
The protocol dosing schedule uses polatuzumab vedotin and rituximab on Day 1, with gemcitabine and oxaliplatin on Day 2. (onlinelibrary.wiley.com)
Dosing schedule (per 21-day cycle)
- Polatuzumab vedotin: 1.8 mg/kg IV once on Day 1 (maximum 240 mg per cycle). (clinicaltrials.gov)
- Rituximab: 375 mg/m² IV once on Day 1. (clinicaltrials.gov)
- Gemcitabine: 1000 mg/m² IV once on Day 2. (onlinelibrary.wiley.com)
- Oxaliplatin: 100 mg/m² IV once on Day 2. (onlinelibrary.wiley.com)
Administration details for polatuzumab vedotin (infusion logistics)
- Polatuzumab vedotin is administered as an IV infusion only. (accessdata.fda.gov)
- IV line patency is confirmed prior to infusion. (accessdata.fda.gov)
- Extravasation monitoring is performed during administration. (accessdata.fda.gov)
- A dedicated infusion line is used with a 0.2- or 0.22-micron low-protein-binding in-line or add-on filter and a catheter. (accessdata.fda.gov)
- Polatuzumab vedotin is not mixed with other drugs and is not administered as a co-infusion with other agents. (accessdata.fda.gov)
Premedication and infusion timing for polatuzumab vedotin
- If not already premedicated, an antihistamine and antipyretic are administered at least 30 minutes prior to polatuzumab vedotin. (accessdata.fda.gov)
- The initial polatuzumab vedotin dose is infused over 90 minutes. (accessdata.fda.gov)
- Patients are monitored for infusion-related reactions during infusion and for a minimum of 90 minutes after completion of the initial dose. (accessdata.fda.gov)
Administration details for rituximab and chemotherapy sequence within the cycle
- Polatuzumab vedotin and rituximab are administered on Day 1 of each 21-day cycle. (clinicaltrials.gov)
- Gemcitabine and oxaliplatin are administered on Day 2 of each 21-day cycle. (onlinelibrary.wiley.com)
Supportive care measures during Pola‑R‑GemOx
- Primary prophylaxis with G-CSF is provided with each cycle as part of the POLARGO supportive-care requirements. (pmc.ncbi.nlm.nih.gov)
- Infection prophylaxis is mandatory in POLARGO with anti-infective prophylaxis against Pneumocystis jirovecii pneumonia and herpes virus. (pmc.ncbi.nlm.nih.gov)
Adverse-reaction monitoring considerations tied to supportive care
- Polatuzumab vedotin-associated myelosuppression is monitored with serial blood counts. (accessdata.fda.gov)
- Infection risk is monitored during therapy with close observation for signs of infection. (accessdata.fda.gov)
- Infusion-related reactions to polatuzumab vedotin are managed by infusion interruption and supportive treatment for Grade 1–3 reactions. (accessdata.fda.gov)
Dose-modification framework for polatuzumab vedotin infusion-related reactions (operational)
- For Grade 1–3 infusion-related reactions: polatuzumab vedotin infusion is interrupted and supportive treatment is given. (accessdata.fda.gov)
- After a Grade 1–3 reaction that resolves, the infusion may be resumed at 50% of the pre-interruption rate. (accessdata.fda.gov)
- If the infusion is well tolerated in a subsequent cycle, later infusions may be administered over 30 minutes. (accessdata.fda.gov)
Iterative cycle structure and duration in POLARGO
- Pola‑R‑GemOx is administered every 21 days for up to 8 cycles in the POLARGO regimen design described in published materials. (onlinelibrary.wiley.com)